Background
==========

First line antiretroviral treatment (ART) regimens in Low and Middle Income Countries (LMICs) of non nucleoside reverse trancriptase inhibitor (NNRTI) with thymidine analogue nucleoside reverse transcriptase inhibitors (tNRTIs) are associated with numerous long term toxicities \[[@B1]\]. The World Health Organization (WHO) has recommended phasing out stavudine (d4T) and using tenofovir (TDF) as component of first line treatment regimens \[[@B2]\]. Amongst those failing first-line tNRTI regimens, TDF with ritonavir boosted PI (PI/r) is recommended as a second line regimen.

Tenofovir based regimens are associated with excellent efficacy and safety in clinical trials \[[@B3]\]. However, these studies have been done in High Income Countries (HICs) and data on their effectiveness and safety in LMICs is limited \[[@B4]-[@B7]\]. Tenofovir has been associated with renal toxicity amongst 1-2% of people living with Human Immunodeficiency Virus (PLHIV) but higher proportion of patients demonstrate a fall in estimated Glomerular Filtration Rate (eGFR) \[[@B8]\]. Traditional risk factors are common amongst PLHIV experiencing renal toxicity to antiretrovirals, although not everybody with these risk factors develops renal adverse events \[[@B9]\]. In Sub-saharan Africa, severe eGFR impairment was infrequent over 4 years irrespective of the use of TDF \[[@B10]\]. The authors of this study conclude that TDF based first line ART can be safely given even without renal monitoring in these settings.

There is no published data on the incidence of TDF induced renal dysfunction amongst PLHIV in India. We determined and compared the incidence of and risk factors for renal impairment associated with TDF use amongst PLHIVs accessing care in a HIC and LMIC setting.

Methods
=======

Setting
-------

People living with HIV accessing care at two clinics: HIC-the Royal Free Hospital (RFH), London, UK and LMIC- Institute of Infectious Diseases (IID), Pune Western India were included

Design
------

This is a retrospective study comparing renal outcomes amongst PLHIV at these two sites. Data was abstracted from clinic electronic and paper records. Approval for the study was given by Chairman's approval letter from the Royal Free Ethics Committee while at Institute of Infectious Diseases all HIV positive persons provide consent on Ethics committee (Chest Research Foundations Independent Ethics Committee, Pune India) approved form mentioning that data collected during the course of care would be used for research analysis. Patient details were annonymized for data analysis.

Study population
----------------

All HIV-1 positive adults initiating TDF for the first time between 1^st^ January 2007 to 31^st^ December 2009 with at least one follow up eGFR measurement were included in the final analysis. At both sites renal evaluations (serum creatinine, urine analysis, serum phosphate, electrolytes) are performed at baseline and every 3 to 6 months after initiation of TDF as standard of care and whenever clinically indicated. At IID PLHIV pay out of pocket for subsidized antiretrovirals (ARVs) and laboratory tests, while National Health Services (NHS) provides for the same at RFH.

Measurements
------------

The eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. However, all analyses were repeated using the Cockroft-Gault (CG) formula and the results were consistent. A recent study amongst Indians has documented optimal performance of MDRD equation for estimating eGFR, while the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation showed marked bias at higher eGFRs \[[@B11]\]. Information on demographic variables at the time of initiating TDF was summarised. An eGFR \>90/ml/min/1.73 m^2^ is considered normal while eGFR \<60 ml/min/1.73 m^2^ considered as decreased. Partial Fanconi's syndrome was diagnosed by the presence of one or more of the following: normoglycemic glycosuria, hypophosphatemia, tubular acidosis and hypouricemia \[[@B12]\]. CD4 counts and Plasma viral loads were determined by flow cytometry and PCR (Roche Taqman, Lower limit of quantification \<40 copies/ml) respectively. Treatment limiting renal toxicity was defined as any renal impairment leading to permanent discontinuation of TDF, including those who demonstrated a declining trend to an eGFR of less than 60 ml/min/1.73 m^2^.

Data analysis
-------------

Characteristics of PLHIV at the time of starting TDF were summarised according to clinical centre. The eGFR at the time of initiating TDF (Baseline; measured within the 6 months previous to initiating TDF), and 6, 12, 18 and 24 months after starting TDF were calculated by creating a window 3 months either side of the time point of interest, and considering the eGFR that occurred within the window closest to this time point. As the eGFR measurements were suitable normally distributed, the eGFR value at each time point, as well as the change in eGFR from baseline were summarised using the mean and standard deviation (SD). Changes over time within and between centres were compared using paired and unpaired t-tests respectively at two pre-defined time points of 6 and 24 months post-TDF initiation.

Finally, the subset of PLHIV with an eGFR \>90 ml/min/1.73 m^2^ when initiating TDF were considered. Time to development of eGFR \< 60 ml/min/1.73 m^2^ was calculated using standard survival methods, with individuals who did not experience the event being censored at the time of the last available eGFR measurement. Factors associated with time to eGFR \< 60 ml/min/1.73 m^2^ were investigated using Cox proportional hazards models. The variables included in this models included site, age, gender, use of concomitant PI/r, pre-TDF and nadir CD4 count, time since HIV diagnosis, and ever receiving PI/r prior to receipt of TDF. No formal adjustments were made for multiple testing. All analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC).

Results
=======

Baseline demographics
---------------------

A total of 574 and 708 HIV positive individuals from RFH and IID respectively initiating TDF based ART were included in the final analysis (Table [1](#T1){ref-type="table"}). All PLHIV at IID were of Indian ethnicity whilst approximately 60% at RFH were Caucasian. Approximately 75% PLHIV at IID were using TDF in an NNRTI based (EFV, NVP) regimen whilst 56% at RFH used TDF in a ritonavir-boosted PI-based regimen. Approximately half of the PLHIV at each site were ARV naive at TDF initiation. At both the sites EFV was the commonest NNRTI used (36.8% at RFH and 48.2% at IID) while LPV/r (26.5%) and ATV/r (17.5%) were the main PIs used at RFH and IID respectively. Median CD4 count at baseline was lower at IID (242 cells/mm^3^ vs 348 cells/mm^3^). Measurement of viral load prior to initiation of ART is not part of routine care at IID. Baseline median eGFR were normal and similar at both sites (102 ml/min/1.73 m^2^ and 100 ml/min/1.73 m^2^ at RFH and IID respectively). Approximately one-third of PLHIV at both sites had eGFR \< 90 ml/min/1.73 m^2^ at baseline (Table [2](#T2){ref-type="table"}).

###### 

Patient characteristics at time of starting tenofovir

                                                                                **Royal Free**               **Pune**
  ------------------------------------------------------ ---------------- -------------------------- ------------------------
  N                                                                              574 (100.0)               708 (100.0)
  Age (years)                                            Median (IQR)            41 (35, 47)               38 (34, 45)
  Gender                                                 Male                     439 (76.5)                537 (75.8)
                                                         Female                   135 (23.5)                171 (24.2)
  Ethnicity                                              White                    339 (59.1)                    \-
                                                         Black                    161 (28.1)                    \-
                                                         Indian                       \-                   708 (100.0)
                                                         Other                    74 (12.9)                     \-
  Risk for HIV transmission                              MSM                      333 (58.0)                    \-
  Heterosexual                                           224 (39.0)                   \-             
                                                         Other                     17 (3.0)                     \-
  CD4 count (cells/mm^3^)                                Median (IQR)       348 (230, 525) N = 571    242 (118, 395) N = 657
  HIV RNA viral load (log copies/ml)                     Median (IQR)      4.2 (\<1.7, 5.0) N = 536            N/A
  ART-naïve when started TDF                             Yes                      314 (54.7)                307 (43.4)
  No                                                     260 (45.3)               401 (56.6)         
  Time since first ART at time of starting TDF (weeks)   Median (IQR)       368 (217, 545) N = 260    162 (66, 274) N = 400
  Other ARVs in regimen                                  Emtricitabine            530 (97.2)                641 (90.5)
                                                         Lamivudine                28 (4.9)                  61 (8.6)
                                                         Zidovudine                10 (1.7)                  62 (8.8)
                                                         Didanosine                1 (0.2)                   1 (0.1)
                                                         Abacavir                  22 (3.8)                  2 (0.2)
                                                         Lopinavir                152 (26.5)                 49 (6.9)
                                                         Atazanavir               88 (15.3)                 125 (17.7)
                                                         Darunavir                 35 (6.1)                  0 (0.0)
                                                         Saquinavir                28 (4.9)                  1 (0.1)
                                                         Fos-amprenavir            16 (2.8)                  0 (0.0)
                                                         Nelfinavir                2 (0.4)                   0 (0.0)
                                                         Ritonavir                308 (53.6)                181 (25.6)
                                                         Efavirenz                211 (36.8)                341 (48.2)
                                                         Nevirapine                50 (8.7)                 183 (25.9)
                                                         Etravirine                7 (1.2)                   0 (0.0)
                                                         T20                       1 (0.2)                   0 (0.0)
                                                         Raltegravir               13 (2.3)                  0 (0.0)
                                                         Maraviroc                 2 (0.4)                   0 (0.0)
                                                         Stavudine                                           13 (1.8)
                                                         Indinavir                                           6 (0.9)
  Baseline eGFR                                          Median (IQR)           102 (89, 117)             100 (82, 119)
  Baseline creatinine                                    Median (IQR)            77 (68, 87)               79 (62, 88)

###### 

**GFR (ml/min/1.73 m**^**2**^**) results using MDRD over follow up**

                                       **Baseline**   **6 mths**   **12 mths**   **18 mths**   **24 mths**
  ----------------------------------- -------------- ------------ ------------- ------------- -------------
  **Royal Free patients**                                                                            
  Number with measure                      574           514           468           364           273
  GFR Mean (SD)                          104 (25)      100 (23)      99 (22)       97 (21)       97 (25)
  Change from baseline                      \-         -4 (19)       -6 (18)       -6 (19)       -7 (21)
  GFR \<90                              150 (26.1)    169 (32.9)   178 (38.0)    128 (35.2)    110 (40.3)
  GFR \< 60                              10 (1.7)      7 (1.4)       8 (1.7)       9 (2.5)      11 (4.0)
  GFR \< 30                              1 (0.2)       1 (0.2)       2 (0.4)       2 (0.6)       0 (0.0)
  P-value for change from baseline                     \<0.0001                                 \<0.0001
  **IID, Pune patients**                                                                             
  Number with measure                      702           439           391           366           302
  GFR Mean (SD)                          105 (35)      97 (28)       96 (28)       98 (29)       96 (31)
  Change from baseline                                 -6 (39)       -7 (38)       -8 (40)       -7 (40)
  GFR \<90                              254 (36.2)    193 (44.0)   195 (49.9)    165 (45.1)    144 (47.7)
  GFR \< 60                              38 (5.4)      28 (6.4)     27 (6.9)      32 (8.7)      23 (7.6)
  GFR \< 30                              2 (0.3)       0 (0.0)       2 (0.5)       2 (0.6)       2 (0.7)
  P-value for change from baseline                     \<0.0001                                   0.001
  P-value for comparison of centres                      0.46                                     0.76

Changes in renal function
-------------------------

Changes in eGFR over follow up at the two sites are summarized in Table [2](#T2){ref-type="table"}. There was a statistically significant decline in eGFR from baseline at 6 and 24 months at both the sites, however there was not a statistically significant difference in eGFR decline between sites. People living with HIV at both sites had an average decline in eGFR of 7 ml/min/1.73 m^2^ at 24 months post TDF-initiation.

Amongst individuals with pre-TDF eGFR \> 90 ml/min/1.73 m^2^, PLHIV at IID were more likely than the RFH to develop an eGFR \< 60 ml/min/1.73 m^2^ (adjusted hazard ratio \[aHR\]: 7.6 p \< 0.0001) (Table [3](#T3){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). Independent risk factors associated with progression to eGFR \< 60 ml/min/1.73 m^2^ included age (per 10 years older aHR: 2.21) and receiving concomitant PI/r (aHR: 2.4). Interestingly, neither CD4 counts at eGFR estimation nor CD4 nadir were associated with significant eGFR decline.

###### 

**Factors associated with HIV positive persons developing (single measurement) eGFR of \<60 ml/min/1.73 m**^**2**^**who had baseline eGFR \> 90 /ml/min1.73/m**^**2**^

                                                        **Univariate**   **Multivariate**                                    
  ------------------------------- -------------------- ---------------- ------------------ ---------- -------- ------------- ---------
                                                            **HR**          **95% CI**       **p**     **HR**   **95% CI**     **p**
  Centre                          Pune                       4.87          2.28, 10.38      \<0.0001    7.65    3.36, 17.41   \<.0001
                                  RF                         1.00               \-                      1.00        \-            
  Age                             Per 10 years older         1.85           1.43, 2.40      \<.00001    2.21    1.61, 3.05    \<.0001
  Gender                          Female                     1.63           0.89, 2.99        0.12      1.72    0.90, 3.29     0.10
                                  Male                       1.00               \-                      1.00        \-            
  Receiving PI                    Yes                        1.01           0.57, 1.79        0.97      2.40    1.21, 4.76     0.01
                                  No                         1.00               \-                      1.00        \-            
  CD4 count                       Per 100 cells              1.01           0.90, 1.13        0.89      1.04    0.89, 1.20     0.65
  Time since diagnosis            Per year longer            0.98           0.92, 1.04        0.46      1.00    0.92, 1.07     0.92
  CD4 nadir                       Per 100 cells              0.94           0.78, 1.14        0.55      0.99    0.79, 1.23     0.91
  Ever received a PI before TDF   Yes                        0.76           0.32, 1.78        0.52      0.77    0.28, 2.15     0.62
                                  No                         1.00               \-                      1.00        \-            

![**Time to progression to eGFR \< 60 m/min/1.73 m**^**2**^**amongst those with baseline eGFR \> 90 ml/min/1.73 m**^**2**^**.** Legend: Time to development of eGFR \< 60 ml/min/1.73 m^2^ as determined by MDRD amongst HIV positive individuals initiating Tenofovir with a baseline eGFR \> 90 ml/min/1.73 m2 at IID, Pune (red) and Royal Free Hospital, UK (blue). The difference across the centres is statistically significant (p \< 0.0001).](1471-2334-14-173-1){#F1}

An eGFR \< 60 ml/min/1.73 m^2^ developed amongst 41 PLHIV at IID and 8 individuals at RFH. Fifteen PLHIV at IID developed partial Fanconi's syndrome (8 with concomitant NNRTI and 7 with boosted PI). Fifty-nine (8.3%) individuals developed treatment limiting toxicity at IID (41with eGFR \< 60 ml/min/1.73 m^2^, 15 partial Fanconi syndrome and 3 acute kidney injury) and 8 individuals developed treatment limiting toxicity (all with eGFR \< 60 ml/min/1.73 m^2^) at RFH. Twenty-one (35.5%) of these PLHIV had co-morbidities (Hypertension-11, Diabetes -9, chronic HCV-1), however we did not perform any formal adjustment analysis due to small sample size. The characteristics of 15 PLHIV with partial Fanconi's syndrome have been summarized in Table [4](#T4){ref-type="table"}.

###### 

Characteristics of HIV positive individuals with partial Fanconi's syndrome

  **Variable**                                                        
  ------------------------------------------------------------------ --------------
  Lab features                                                        
  Normoglycemic glycosuria with hypophosphatemia                     11
  Normoglycemic glycosuria with hypokalemia and metabolic acidosis   1
  Normoglycemic glycosuria and hypouricemia                          1
  Hypophosphatemia                                                   2
  Medain age (range)                                                 54.3 (42-67)
  Gender                                                              
  Male                                                               9
  Median duration of TDF, weeks (range)                              92 (24-188)
  Co-morbidities                                                      
  None                                                               13
  Hypertension                                                       2
  Concomitant ARV                                                     
  NVP                                                                5
  EFV                                                                3
  ATV/r                                                              5
  LPV/r                                                              2

Discussion
==========

To our knowledge, this is the first comparison of TDF associated renal dysfunction, amongst PLHIV accessing care in HIC and LMIC clinics. The WHO has recommended scaling up TDF based first line ARV regimens in LMICs. While we and others have demonstrated the effectiveness of TDF based first line regimens there is limited data on the safety, especially renal and bone toxicity in LMICs \[[@B13],[@B14]\].

Although the change in eGFR from baseline were similar amongst PHIV at both sites, we found significantly higher frequency of treatment limiting renal toxicity and a higher risk of developing an eGFR \< 60 ml/min/1.73 m^2^ associated with TDF in Western India. Weight was not included as a covariate in analysis, as when the results were repeated using the CG formula (which includes weight), consistent results were obtained However, weight/creatinine ratio has been associated with renal toxicity and perhaps current recommended dose of TDF may be high for Indians \[[@B15],[@B16]\].

At both sites significant risk factors associated with reduction in eGFR were age and concomitant PI/r. Use of concomitant PI/r has been associated with higher risk of renal toxicity in individuals taking TDF \[[@B17]\]. Inhibition of Multi-Resistance Protein (MRP-4) efflux channels in the proximal convoluted tubules by ritonavir may contribute to this \[[@B18]\]. Renal dysfunction has been documented to be more common when TDF is combined with ATV/r as compared to LPV/r, although varying follow up times may have accounted for the difference in this study \[[@B19]\]. When TDF is used with PI/r in second line regimens in RLS, monitoring for renal toxicity is warranted. This also argues for using TDF in first line regimens with NNRTIs.

Risk factors associated with treatment limiting nephrotoxicity in our study included Diabetes, Hypertension, and receipt of concomitant nephrotoxic medications. It would be prudent to perform frequent renal monitoring or to avoid the use of TDF in the presence of these risk factors. Predictors of significant nephrotoxicity such as pre-existing renal impairment, older age, advanced HIV disease, vasculometabolic disease, low body weight have been well documented \[[@B16],[@B20]\]. In addition careful renal monitoring is warranted amongst HIV positive individuals with acute inter-current illnesses.

The clinical presentations of treatment limiting renal toxicity seen at IID included progression to eGFR \< 60 ml/min/1.73 m^2^, Acute Kidney Injury and partial Fanconi's syndrome. Two of the HIV positive individuals were diagnosed as having partial Fanconi's syndrome on the basis of only profound hypophosphatemia (serum phopshorus \<1.5 mg/dl) and one patient with hypouricemia (Serum uric acid 1.9 mg/dl) and normoglycemic glycosuria. Although this is controversial, we did not have access to other tests for assessing tubular dysfunction like aminoaciduria, tubular proteinuria, and fractional excretion of phosphate. Partial Fanconi's syndrome may present without eGFR decline, hence high clinical suspicion (e.g. proximal muscle weakness) and routine monitoring for glycosuria (triggering blood glucose determination to confirm normoglycemic glycosuria) is needed. Other components like aminoaciduria, tubular proteinuria and tubular acidosis needed to define Fanconi's syndrome may not be routinely available in LMICs.

Our study has several limitations aside from the retrospective observational design. We have reported eGFR estimated using the MDRD formula, although consistent results were obtained when in a sensitivity analysis using the CG formula. The small sample size precludes interpretation of the incidence and adjustments for risk factors associated with renal impairment have not been included in the analysis. We have used a single eGFR \< 60 ml/min/1.73 m^2^ estimation in the analysis that can indicate incident CKD, AKI or creatinine blips or laboratory errors. Additionally we have not included urine analysis data, although glycosuria (normoglycemic glcosuria) was used as a trigger to investigate for partial Fanconi syndrome. Comparing two different populations at two different settings with differing standards of practice also limits external validity.

Conclusions
===========

In summary, renal dysfunction was more commonly associated with the use of TDF based regimens in Western India compared to PLHIV in the UK. As TDF based regimens are being scaled up in LMICs, early identification and management of various forms of TDF induced renal injury would need renal monitoring (especially those with background risk factors for renal disease) and physician training. Exploring alternative strategies like lowering TDF dose and use of alternative formulations like TDF alefenamide (TAF) also needs to be urgently studied in these settings.
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